Trial Profile
Antiviral activity, safety, and tolerability of a novel, oral small-molecule HIV-1 attachment inhibitor BMS-488043, in HIV-1 infected subjects.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Feb 2011
Price :
$35
*
At a glance
- Drugs BMS 488043 (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 15 Nov 2010 Results published online ahead of print in Antimicrobial Agents and Chemotherapy,
- 05 Nov 2010 New trial record.